15289-s-bos

116 | Chapter 7 22. Leebmann J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease prospective observational multicenter study. Circulation 2013; 128:2567-2576. 23. Rosada A, Kassner U, Vogt A et al. Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events? Artif Organs 2013. 24. Villines TC, Kim AS, Gore RS, Taylor AJ. Niacin: The evidence, clinical use, and future directions. Curr Atheroscler Rep 2012; 14:49-59. 25. Albers JJ, Slee A, O’Brien KD et al. Relationship of apolipoproteins A-1 and b, and lipoprotein(a) to cardiovascular outcomes: The aim-high trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol 2013; 62:1575-1579. 26. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013; 61:440-446. 27. Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther 2014; 19:141-158. 28. Ginsberg HN, Reyes-Soffer G. Niacin: a long history, but a questionable future. Curr Opin Lipidol 2013; 24:475-479. 29. Moutzouri E, Liberopoulos EN, Tellis CC et al. Comparison of the effect of simvastatin versus simvastatin/ ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 2013; 231:8-14. 30. Stein EA, Dufour R, Gagne C etal. Apolipoprotein B Synthesis InhibitionwithMipomersen inHeterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients with Coronary Artery Disease. Circulation 2012; 126:2283-2292. 31. Thomas GS, Cromwell WC, Ali S et al. Mipomersen, an apolipoprotein b synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013; 62:2178-2184. 32. Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46. 33. Teramoto T, Shirakawa M, Kikuchi M et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis 2013; 230:52-60. 34. Gotto AM, Jr., Kher U, Chatterjee MS et al. Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. J Cardiovasc Pharmacol Ther 2014. 35. Teramoto T, Takeuchi M, Morisaki Y et al. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Am J Cardiol 2014; 113:2021-2029. 36. Davidson MH. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidology 2013; 7:S11-S15. 37. Desai NR, Kohli P, Giugliano RP et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 Trial. Circulation 2013; 128:962-969. 38. Raal F, Stein E, Scott R et al. Reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD): Results from a phase 2, randomized, double-blind, placebo-controlled trial. Circulation 2012; 126:2781-2782. 39. Blom DJ, Hala T, Bolognese M et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. The New England journal of medicine 2014; 370:1809-1819. 40. Viney N, GrahamM, Crooke R et al. Evaluation of Isis APO(A)RX, an antisense inhibitor to apolipoprotein(a), in healthy volunteers. Circulation 2013; 128. 41. Jacobson TA. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 2013; 88:1294-1311.